The controversies surrounding these treatment protocols may include the specificity and potential off-target effects of HIF-2α inhibition, the translational relevance of findings from animal models to human PAH patients, and the need for further clinical studies to validate the efficacy and safety of PT2567 and sildenafil in human PAH populations. This evidence concerns the gene EPAS1 and pulmonary arterial hypertension.